The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)) / Galsky, M.D., Bajorin, D.F., Witjes, J.A., Gschwend, J.E., Tomita, Y., Nasroulah, F., Li, J., Collette, S., Valderrama, B.P., Grimm, M.-O., Appleman, L., Gravis, G., Necchi, A., Ye, D., Stenner, F., Wind-Rotolo, M., Zhang, J., Unsal-Kacmaz, K.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 85:3(2024), pp. e96-e97. [10.1016/j.eururo.2023.12.013]

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))

Necchi A.;
2024-01-01

Abstract

The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.
2024
Inglese
Elsevier B.V.
85
3
e96
e97
Pubblicato
Esperti anonimi
Internazionale
Goal 3: Good health and well-being
Sì
Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)) / Galsky, M.D., Bajorin, D.F., Witjes, J.A., Gschwend, J.E., Tomita, Y., Nasroulah, F., Li, J., Collette, S., Valderrama, B.P., Grimm, M.-O., Appleman, L., Gravis, G., Necchi, A., Ye, D., Stenner, F., Wind-Rotolo, M., Zhang, J., Unsal-Kacmaz, K.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 85:3(2024), pp. e96-e97. [10.1016/j.eururo.2023.12.013]
none
18
info:eu-repo/semantics/article
262
Galsky, M. D.; Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Tomita, Y.; Nasroulah, F.; Li, J.; Collette, S.; Valderrama, B. P.; Grimm, M. -O.; Appl...espandi
1 Contributo su Rivista::1.1.5. Erratum
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/208401
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact